Renaissance Technologies
DNTH icon

Renaissance Technologies’s Dianthus Therapeutics DNTH Stock Holding History

Renaissance Technologies’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,100
Closed -$1.32M – 3339
2025
Q4 		$1.32M Buy
+32,100
New +$1.24M ﹤0.01% 2117
2024
Q4 		– Sell
-55,416
Closed -$1.52M – 3646
2024
Q3 		$1.52M Sell
55,416
-33,188
-37% -$924K ﹤0.01% 2192
2024
Q2 		$2.29M Sell
88,604
-17,100
-16% -$411K ﹤0.01% 1801
2024
Q1 		$3.17M Buy
105,704
+56,398
+114% +$1.23M 0.01% 1734
2023
Q4 		$513K Buy
49,306
+14,090
+40% +$156K ﹤0.01% 2760
2023
Q3 		$481K Buy
35,216
+5,110
+17% +$64.4K ﹤0.01% 2718
2023
Q2 		$365K Buy
30,106
+5,518
+22% +$62.8K ﹤0.01% 3038
2023
Q1 		$313K Sell
24,588
-12,157
-33% -$135K ﹤0.01% 3094
2022
Q4 		$232K Buy
36,745
+11,442
+45% +$203K ﹤0.01% 3352
2022
Q3 		$571K Sell
25,303
-20,406
-45% -$559K ﹤0.01% 2851
2022
Q2 		$878K Buy
45,709
+30,755
+206% +$760K ﹤0.01% 2799
2022
Q1 		$694K Buy
14,954
+11,999
+406% +$656K ﹤0.01% 2977
2021
Q4 		$209K Buy
2,955
+1,436
+95% +$144K ﹤0.01% 3489
2021
Q3 		$177K Buy
+1,519
New +$177K ﹤0.01% 3229
2021
Q1 		– Sell
-13,388
Closed -$1.68M – 3393
2020
Q4 		$1.68M Sell
13,388
-9,281
-41% -$1.05M ﹤0.01% 2225
2020
Q3 		$2.47M Buy
22,669
+9,525
+72% +$1.13M ﹤0.01% 2003
2020
Q2 		$1.58M Buy
13,144
+2,535
+24% +$357K ﹤0.01% 2310
2020
Q1 		$1.07M Buy
+10,609
New +$1.97M ﹤0.01% 2393

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's DNTH Position: Q1 2026 in Review

Renaissance Technologies sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 32,100 shares — an estimated $1.32M sold.

Renaissance Technologies first reported a position in DNTH in Q1 2020 and held it in 18 quarters. The position peaked at $3.17M in Q1 2024. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Renaissance Technologies reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 32,100 Dianthus Therapeutics shares in Q1 2026, an estimated $1.32M.
  • Renaissance Technologies first reported a position in Dianthus Therapeutics in Q1 2020 and held it in 18 quarters.
  • Renaissance Technologies's Dianthus Therapeutics position peaked at $3.17M in Q1 2024.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.